News
Press Releases
.jpg)
-
- 14
- 2022/05
Responding to the Call of the Government, Shanghai Tongyong Pharmaceutical Co., Ltd. Actively Resumed Work and Production
On May 2, Shanghai Tongyong Pharmaceutical Co., Ltd., a subsidiary of Sino Biopharm (HK.01177), became a key enterprise on the white list approved by the Shanghai Municipal Government for resumption of work and production. The first batch of 15 people have been stationed in the plant on May 11 and will be managed in a closed loop according to the epidemic prevention and control requirements thereafter.View > -
- 10
- 2022/05
Sino Biopharm: More Green Energy, Less Resource Waste
Green manufacturing is an important means to solve national resource and environmental problems, and it is also an inevitable choice for enterprises to take the initiative to assume social responsibility. Paying attention to the efficiency of using resources such as energy, water and packaging materials is a very important part of the process.View > -
- 28
- 2022/04
Sino Biopharm-Nanjing Chia Tai TianQing Pharmaceutical Co., Ltd. Was Awarded the Title of "National Worker Pioneer"
We are the answer to the questionnaire of the times. On the eve of "May Day" International Labor Day, the Nanjing Chia Tai TianQing Pharmaceutical Co., Ltd. was awarded the title of "National Worker Pioneer" by the All-China Federation of Trade Unions.View > -
- 26
- 2022/04
Sino Biopharm-Nanjing Chia Tai TianQing's Invention Patent Won the China Patent Excellence Award
Recently, China National Intellectual Property Administration announced the results of the twenty-third China Patent Award, and CTTQ's invention patent "Solvents of Raltitrexed and its preparation method" won the China Patent Excellence Award.View > -
- 20
- 2022/04
Integrating "green development" into the Corporate's DNA! Sino Biopharm is Deeply Engaged in the Green Transformation of the Pharmaceutical Industry
Climate change is a serious challenge facing mankind in the 21st century. In recent years, in the face of global warming, extreme weather and other challenges, Sino Biopharm has resolutely implemented the concept of green development, actively participated in China's "2030 Carbon Peak, 2060 Carbon Neutral" independent emission reduction strategy, and committed to build an environmentally friendly low-carbon enterprise.View > -
- 18
- 2022/04
China Medical Development Conference Held in Beijing - Group President Ms. Cheng Cheung Ling Attended and Executive Director Mr. Tse, Eric S Y Delivered a Speech
In order to implement the important instruction of President Xi Jinping to "strive to build the Chinese Academy of Medical Sciences into the core base of China's medical science and technology innovation system", based on the new development stage, implement the new development concept, build a new development pattern,View > -
- 14
- 2022/04
Sino Biopharm and CTTQ Donate Urgently Needed Epidemic Prevention Supplies to Shanghai
Recently, the situation of the epidemic in Shanghai has concerned the whole nation. Ms. Cheng Cheung Ling, Vice Chairman of the Board of Directors of Sino Biopharm and Chairman of Beijing Tide Pharmaceuticals, Mr. Tse, Eric S Y, Executive Director and Chief Operating Officer of Sino Biopharm and Chairman of CTTQ Pharmaceuticals,View > -
- 13
- 2022/04
Sino Biopharm "Anlotinib" Approved for Fifth Indication
On April 13, Sino Biopharm received approval for a new indication for its Anlotinib Hydrochloride Capsules, presumably for differentiated thyroid cancer. This is the fifth indication for the drug to be approved in China.View > -
- 08
- 2022/04
Sino Biopharm Innovation "TQ-B3525" included in CDE's list of Breakthrough Therapy Drugs
On April 8, Sino Biopharm announced that the Group's self-developed innovative drug "TQ-B3525" has been included in the list of breakthrough therapeutics by the China Center for Drug Evaluation (CDE) of the State Drug Administration for relapsed/refractory follicular lymphoma that has failed at least second-line therapy.View > -
- 02
- 2022/04
CP Pharmaceutical Group President Ms. Cheng Cheung Ling Donated 800,000 COVID-19 Test Kits on Behalf of the Group to Help Jilin Fight the Epidemic
The COVID-19 epidemic spread in Jilin Province has concerned all walks of life since its outbreak in late February. Recently, the number of confirmed cases has increased repeatedly, the situation is still serious and the difficulty of prevention and control has been increasing.In order to help Jilin fight against the epidemic and achieve victory as soon as possible, Ms. Cheng Cheung Ling, President of CP Pharmaceutical Group,View >